ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia

5Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Acute myeloid leukaemia (AML) is a blood cancer with a heterogeneous genomic landscape. This study aimed to mine bioinformatics data generated by RNA sequencing to unveil an AML case transcriptome profile and identify novel therapeutic targets and markers. In this study, we have determined the transcriptomic profile and analysed gene variants of an AML patient at the time of diagnosis and validated some genes by quantitative reverse transcriptase polymerase chain reaction. ADAMTS14, ARHGAP22, and ependymin-related protein 1 (EPDR1) were markedly upregulated compared to the corresponding control. In addition, novel exonic single-nucleotide and insertion/deletion variants were identified in these genes. Hence, ADAMTS14, ARHGAP22, and EPDR1 can be proposed as potential novel targets in AML, and their exact roles should be further explored.

Cite

CITATION STYLE

APA

El-Masry, O. S., Alamri, A. M., Alzahrani, F., & Alsamman, K. (2022). ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia. Heliyon, 8(3). https://doi.org/10.1016/j.heliyon.2022.e09065

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free